Kodiak Sciences ($KOD) delivered the kind of binary clinical catalyst that can reset a biotech stock in minutes: shares jumped roughly 65% in premarket trading, reaching $54.42, after the company reported positive Phase 3 DAYBREAK results.

The move followed a 7% gain ahead of the topline data release, putting the stock’s reaction firmly in the high-volatility category. For traders, the headline is straightforward; the harder question is how much of the clinical de-risking is already reflected in the initial price reaction.

DAYBREAK clears its primary endpoints

According to the company announcement reported by MarketScreener, the Phase 3 DAYBREAK study met its primary endpoints for both Zenkuda, also known as tarcocimab tedromer, and tabirafusp-ted, or KSI-501.

The trial involved patients with wet age-related macular degeneration. That matters because the result is not a preliminary signal from an early-stage study; it is a positive readout from a Phase 3 program involving two named treatment candidates. The supplied data do not provide additional efficacy percentages, safety figures, or regulatory timelines, so the analysis should remain anchored to the endpoint result rather than extend beyond it.

Why the market reaction is so large

A successful pivotal-stage trial can represent a major de-risking event for a clinical-stage biotech. Before a decisive readout, the market is weighing the possibility that a candidate may fail to demonstrate the required benefit. Once primary endpoints are met, one layer of that uncertainty may be reduced.

That does not eliminate development or commercial uncertainty. The result still has to be interpreted alongside the broader development path, potential regulatory considerations, future execution, and the commercial opportunity for the treatments. None of those additional data points are supplied here, but they are precisely why a sharp first reaction should not be treated as a complete long-term valuation framework.

Trader focus: reaction versus next phase

The scale of the move makes $KOD a clear example of binary-event trading. A roughly 65% premarket jump to $54.42 is the market’s immediate response to the DAYBREAK endpoint announcement. The earlier 7% advance shows that expectations were already moving before the topline release, but the post-readout move was materially larger.

That sequence creates two separate analytical questions:

• Did the clinical result meet the stated trial objective? Based on the announcement, DAYBREAK met its primary endpoints for both Zenkuda and tabirafusp-ted.
• Does the initial repricing establish the stock’s longer-term path? The supplied information does not answer that question.

For traders, the distinction is critical. A binary catalyst can compress months of uncertainty into a single premarket session, while the following phase may focus less on whether the study succeeded and more on how the company advances the candidates. With no supplied volume, valuation, or additional price data, it would be premature to infer more than the documented move.

Coverage from Blockonomi describes the roughly 65% reaction, while GuruFocus captures the 7% move ahead of the data. Together with the MarketScreener report on the company announcement, those figures frame the event: a major Phase 3 milestone followed by an outsized market repricing.